NCT07069270View on ClinicalTrials.gov

A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

January 1, 2028

Conditions
VunakizumabAdebrelimabSmall Cell Lung Cancer
Interventions
DRUG

Vunakizumab (IL-17A inhibitor)

Vunakizumab , 240mg, D1, subcutaneous injection, Q4W.

DRUG

Adebrelimab

Adebrelimab, 1200 mg, D1, intravenous drip, Q3W

DRUG

Chemotherapy

Etoposide, 100mg /m², D1-3, IV, Q3W. Carboplatin, AUC 5, D1, IV, Q3W

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV